Potent anti-angiogenic motifs within the Alzheimer β-amyloid peptide

References

• Gorevic P D, Goni F, Pons-Estel B, Alvarez F, Peress N S, Frangione B. Isolation and partial characterization of neurofibrillary tangles and amyloid plaque core in Alzheimer's disease: immunohistological studies. J Neuropathol Exp Neurol 1986; 45: 647–664
   PubMed Web of Science ®Google Scholar
• Selkoe D J, Abraham C R, Podlisny M B, Duffy L K. Isolation of low-molecular-weight proteins from amyloid plaque fibers in Alzheimer's disease. J Neurochem 1986; 46: 1820–1834
   PubMed Web of Science ®Google Scholar
• Pardridge W M, Vinters H V, Yang J, Eisenberg J, Choi T B, Tourtellotte W W, Huebner V, Shively J E. Amyloid angiopathy of Alzheimer's disease: amino acid composition and partial sequence of a 4,200-dalton peptide isolated from cortical microvessels. J Neurochem 1987; 49: 1394–1401
   PubMed Web of Science ®Google Scholar
• Jellinger K A, Attems J. Prevalence and pathogenic role of cerebrovascular lesions in Alzheimer disease. J Neurol Sci 2005; 229–230: 37–41
   PubMed Web of Science ®Google Scholar
• Paris D, Town T, Parker T, Humphrey J, Mullan M. A beta vasoactivity: an inflammatory reaction. Ann NY Acad Sci 2000; 903: 97–109
   PubMed Web of Science ®Google Scholar
• Johnson N A, Jahng G H, Weiner M W, Miller B L, Chui H C, Jagust W J, Gorno-Tempini M L, Schuff N. Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience. Radiology 2005; 234: 851–859
   PubMed Web of Science ®Google Scholar
• Nicoll J A, Yamada M, Frackowiak J, Mazur-Kolecka B, Weller R O. Cerebral amyloid angiopathy plays a direct role in the pathogenesis of Alzheimer's disease. Pro-CAA position statement. Neurobiol Aging 2004; 25: 589–597
   PubMed Web of Science ®Google Scholar
• Paris D, Quadros A, Humphrey J, Patel N, Crescentini R, Crawford F, Mullan M. Nilvadipine antagonizes both Abeta vasoactivity in isolated arteries, and the reduced cerebral blood flow in APPsw transgenic mice. Brain Res 2004; 999: 53–61
   PubMed Web of Science ®Google Scholar
• Beckmann N, Schuler A, Mueggler T, Meyer E P, Wiederhold K H, Staufenbiel M, Krucker T. Age-dependent cerebrovascular abnormalities and blood flow disturbances in APP23 mice modeling Alzheimer's disease. J Neurosci 2003; 23: 8453–8459
   PubMed Web of Science ®Google Scholar
• Farkas E, Luiten P G. Cerebral microvascular pathology in aging and Alzheimer's disease. Prog Neurobiol 2001; 64: 575–611
   PubMed Web of Science ®Google Scholar
• Wu Z, Guo H, Chow N, Sallstrom J, Bell R D, Deane R, Brooks A I, Kanagala S, Rubio A, Sagare A, Liu D, Li F, Armstrong D, Gasiewicz T, Zidovetzki R, Song X, Hofman F, Zlokovic B V. Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease. Nat Med 2005; 11: 959–965
   PubMed Web of Science ®Google Scholar
• Paris D, Patel N, DelleDonne A, Quadros A, Smeed R, Mullan M. Impaired angiogenesis in a transgenic mouse model of cerebral amyloidosis. Neurosci Lett 2004; 366: 80–85
   PubMed Web of Science ®Google Scholar
• Kouznetsova E, Klingner M, Sorger D, Sabri O, Grossmann U, Steinbach J, Scheunemann M, Schliebs R. Developmental and amyloid plaque-related changes in cerebral cortical capillaries in transgenic Tg2576 Alzheimer mice. Int J Dev Neurosci 2006; 24: 187–193
   PubMed Web of Science ®Google Scholar
• Paris D, Townsend K, Quadros A, Humphrey J, Sun J, Brem S, Wotoczek-Obadia M, DelleDonne A, Patel N, Obregon D F, Crescentini R, Abdullah L, Coppola D, Rojiani A M, Crawford F, Sebti S M, Mullan M. Inhibition of angiogenesis by Abeta peptides. Angiogenesis 2004; 7: 75–85
   PubMedGoogle Scholar
• Cantara S, Donnini S, Morbidelli L, Giachetti A, Schulz R, Memo M, Ziche M. Physiological levels of amyloid peptides stimulate the angiogenic response through FGF-2. FASEB J 2004; 18: 1943–1945
   PubMed Web of Science ®Google Scholar
• Gebbink M F, Voest E E, Reijerkerk A. Do antiangiogenic protein fragments have amyloid properties?. Blood 2004; 104: 1601–1605
   PubMed Web of Science ®Google Scholar
• Serpell L C. Alzheimer's amyloid fibrils: structure and assembly. Biochim Biophys Acta 2000; 1502: 16–30
   PubMed Web of Science ®Google Scholar
• Griffioen A W, van der Schaft D W, Barendsz-Janson A F, Cox A, Struijker Boudier H A, Hillen H F, Mayo K H. Anginex, a designed peptide that inhibits angiogenesis. Biochem J 2001; 354: 233–242
   PubMed Web of Science ®Google Scholar
• Dings R P, Arroyo M M, Lockwood N A, van Eijk L I, Haseman J R, Griffioen A W, Mayo K H. Beta-sheet is the bioactive conformation of the anti-angiogenic anginex peptide. Biochem J 2003; 373: 281–288
   PubMed Web of Science ®Google Scholar
• Skovseth D K, Veuger M J, Sorensen D R, De Angelis P M, Haraldsen G. Endostatin dramatically inhibits endothelial cell migration, vascular morphogenesis, and perivascular cell recruitment in vivo. Blood 2005; 105: 1044–1051
   PubMed Web of Science ®Google Scholar
• Paris D, Ait-Ghezala G, Mathura V S, Patel N, Quadros A, Laporte V, Mullan M. Anti-angiogenic activity of the mutant Dutch Aβ peptide on human brain microvascular endothelial cells. Brain Res Mol Brain Res 2005; 136: 212–230
   PubMedGoogle Scholar
• Cardin A D, Weintaub H JR. Molecular modeling of protein glycosaminoglycan interactions. Arteriosclerosis 1989; 9: 21–32
   PubMedGoogle Scholar
• Snow A D, Kinsella M G, Parks E, Sekiguchi R T, Miller J D, Kimata K, Wight T N. Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, decorin, and versican) to the beta-amyloid protein of Alzheimer's disease. Arch Biochem Biophys 1995; 320: 84–95
   PubMed Web of Science ®Google Scholar
• McLaurin J, Fraser P E. Effect of amino-acid substitutions on Alzheimer's amyloid-beta peptide-glycosaminoglycan interactions. Eur J Biochem 2000; 267: 6353–6361
   PubMedGoogle Scholar
• McKeon J, Holland L A. Determination of dissociation constants for a heparin-binding domain of amyloid precursor protein and heparins or heparan sulfate by affinity capillary electrophoresis. Electrophoresis 2004; 25: 1243–1248
   PubMedGoogle Scholar
• Moon J J, Matsumoto M, Patel S, Lee L, Guan J L, Li S. Role of cell surface heparan sulfate proteoglycans in endothelial cell migration and mechanotransduction. J Cell Physiol 2005; 203: 166–176
   PubMed Web of Science ®Google Scholar
• Tkachenko E, Rhodes J M, Simons M. Syndecans: new kids on the signaling block. Circ Res 2005; 96: 488–500
   PubMed Web of Science ®Google Scholar
• Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005; 16: 159–178
   PubMed Web of Science ®Google Scholar
• Leveugle B, Scanameo A, Ding W, Fillit H. Binding of heparan sulfate glycosaminoglycan to beta-amyloid peptide: inhibition by potentially therapeutic polysulfated compounds. Neuroreport 1994; 5: 1389–1392
   PubMed Web of Science ®Google Scholar
• Kisilevsky R, Szarek W A. Novel glycosaminoglycan precursors as anti-amyloid agents part II. J Mol Neurosci 2002; 19: 45–50
   PubMed Web of Science ®Google Scholar
• Morimoto A, Irie K, Murakami K, Masuda Y, Ohigashi H, Nagao M, Fukuda H, Shimizu T, Shirasawa T. Analysis of the secondary structure of beta-amyloid (Abeta42) fibrils by systematic proline replacement. J Biol Chem 2004; 279: 52781–52788
   PubMed Web of Science ®Google Scholar
• Irie K, Murakami K, Masuda Y, Morimoto A, Ohigashi H, Ohashi R, Takegoshi K, Nagao M, Shimizu T, Shirasawa T. Structure of beta-amyloid fibrils and its relevance to their neurotoxicity: implications for the pathogenesis of Alzheimer's disease. J Biosci Bioeng 2005; 99: 437–447
   PubMed Web of Science ®Google Scholar
• Mathura V S, Paris D, Ait-Ghezala G, Quadros A, Patel N S, Kolippakkam D N, Volmar C H, Mullan M J. Model of Alzheimer's disease amyloid-beta peptide based on a RNA binding protein. Biochem Biophys Res Commun 2005; 332: 585–592
   PubMed Web of Science ®Google Scholar
• Olofsson A, Sauer-Eriksson A E, Ohman A. The solvent protection of Alzheimer amyloid-beta-(1–42) fibrils as determined by solution NMR spectroscopy. J Biol Chem 2006; 281: 477–483
   PubMed Web of Science ®Google Scholar
• Clementi M E, Pezzotti M, Orsini F, Sampaolese B, Mezzogori D, Grassi C, Giardina B, Misiti F. Alzheimer's amyloid beta-peptide (1–42) induces cell death in human neuroblastoma via bax/bcl-2 ratio increase: an intriguing role for methionine 35. Biochem Biophys Res Commun 2006; 342: 206–213
   PubMed Web of Science ®Google Scholar
• Misiti F, Sampaolese B, Pezzotti M, Marini S, Coletta M, Ceccarelli L, Giardina B, Clementi M E. Abeta(31–35) peptide induce apoptosis in PC 12 cells: contrast with Abeta(25–35) peptide and examination of underlying mechanisms. Neurochem Int 2005; 46: 575–583
   PubMed Web of Science ®Google Scholar
• Ferreiro E, Resende R, Costa R, Oliveira C R, Pereira C M. An endoplasmic-reticulum-specific apoptotic pathway is involved in prion and amyloid-beta peptides neurotoxicity. Neurobiol Dis 2006; 23: 669–678
   PubMed Web of Science ®Google Scholar
• Magrane J, Christensen R A, Rosen K M, Veereshwarayya V, Querfurth H W. Dissociation of ERK and Akt signaling in endothelial cell angiogenic responses to beta-amyloid. Exp Cell Res 2006; 312: 996–1010
   PubMed Web of Science ®Google Scholar
• van Horssen J, Otte-Holler I, David G, Maat-Schieman M L, van den Heuvel L P, Wesseling P, de Waal R M, Verbeek M M. Heparan sulfate proteoglycan expression in cerebrovascular amyloid beta deposits in Alzheimer's disease and hereditary cerebral hemorrhage with amyloidosis (Dutch) brains. Acta Neuropathol (Berl) 2001; 102: 604–614
   PubMed Web of Science ®Google Scholar
• Rusnati M, Presta M. Interaction of angiogenic basic fibroblast growth factor with endothelial cell heparan sulfate proteoglycans. Biological implications in neovascularization. Int J Clin Lab Res 1996; 26: 15–23
   PubMedGoogle Scholar
• Dougher A M, Wasserstrom H, Torley L, Shridaran L, Westdock P, Hileman R E, Fromm J R, Anderberg R, Lyman S, Linhardt R J, Kaplan J, Terman B I. Identification of a heparin binding peptide on the extracellular domain of the KDR VEGF receptor. Growth Factors 1997; 14: 257–268
   PubMed Web of Science ®Google Scholar
• Mousa S A, Mohamed S. Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor. Thromb Haemost 2004; 92: 627–633
   PubMed Web of Science ®Google Scholar
• Ashikari-Hada S, Habuchi H, Kariya Y, Kimata K. Heparin regulates vascular endothelial growth factor165-dependent mitogenic activity, tube formation, and its receptor phosphorylation of human endothelial cells. Comparison of the effects of heparin and modified heparins. J Biol Chem 2005; 280: 31508–31515
   PubMed Web of Science ®Google Scholar
• Norrby K. Low-molecular-weight heparins and angiogenesis. APMIS 2006; 114: 79–102
   PubMed Web of Science ®Google Scholar
• Yang S P, Kwon B O, Gho Y S, Chae C B. Specific interaction of VEGF165 with beta-amyloid, and its protective effect on beta-amyloid-induced neurotoxicity. J Neurochem 2005; 93: 118–127
   PubMed Web of Science ®Google Scholar
• Lindahl B, Westling C, Gimenez-Gallego G, Lindahl U, Salmivirta M. Common binding sites for beta-amyloid fibrils and fibroblast growth factor-2 in heparan sulfate from human cerebral cortex. J Biol Chem 1999; 274: 30631–30635
   PubMed Web of Science ®Google Scholar
• Iozzo R V, San Antonio J D. Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena. J Clin Invest 2001; 108: 349–355
   PubMed Web of Science ®Google Scholar
• Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005; 16: 159–178
   PubMed Web of Science ®Google Scholar
• Sanderson R D, Yang Y, Kelly T, Macleod V, Dai Y, Theus A. Enzymatic remodeling of heparan sulfate proteoglycans within the tumor microenvironment: Growth regulation and the prospect of new cancer therapies. J Cell Biochem 2005; 96: 897–905
   PubMed Web of Science ®Google Scholar
• Castillo G M, Lukito W, Wight T N, Snow A D. The sulfate moieties of glycosaminoglycans are critical for the enhancement of beta-amyloid protein fibril formation. J Neurochem 1999; 72: 1681–1687
   PubMed Web of Science ®Google Scholar
• Cohlberg J A, Li J, Uversky V N, Fink A L. Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from alpha-synuclein in vitro. Biochemistry 2002; 41: 1502–1511
   PubMed Web of Science ®Google Scholar
• Kalaria R N, Cohen D L, Premkumar D R, Nag S, LaManna J C, Lust W D. Vascular endothelial growth factor in Alzheimer's disease and experimental cerebral ischemia. Brain Res Mol Brain Res 1998; 62: 101–105
   PubMedGoogle Scholar
• Tarkowski E, Issa R, Sjogren M, Wallin A, Blennow K, Tarkowski A, Kumar P. Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer's disease and vascular dementia. Neurobiol Aging 2002; 23: 237–243
   PubMed Web of Science ®Google Scholar
• Buee L, Hof P R, Delacourte A. Brain microvascular changes in Alzheimer's disease and other dementias. Ann NY Acad Sci 1997; 826: 7–24
   PubMed Web of Science ®Google Scholar
• Slevin M, Krupinski J, Slowik A, Rubio F, Szczudlik A, Gaffney J. Activation of MAP kinase (ERK-1/ERK-2), tyrosine kinase and VEGF in the human brain following acute ischaemic stroke. Neuroreport 2000; 11: 2759–2764
   PubMed Web of Science ®Google Scholar
• Shore P M, Jackson E K, Wisniewski S R, Clark R S, Adelson P D, Kochanek P M. Vascular endothelial growth factor is increased in cerebrospinal fluid after traumatic brain injury in infants and children. Neurosurgery 2004; 54: 605–611
   PubMed Web of Science ®Google Scholar
• Koistinaho M, Kettunen M I, Goldsteins G, Keinanen R, Salminen A, Ort M, Bures J, Liu D, Kauppinen R A, Higgins L S, Koistinaho J. Beta-amyloid precursor protein transgenic mice that harbor diffuse A beta deposits but do not form plaques show increased ischemic vulnerability: role of inflammation. Proc Natl Acad Sci USA 2002; 99: 1610–1615
   PubMed Web of Science ®Google Scholar
• Wen Y, Yang S, Liu R, Brun-Zinkernagel A M, Koulen P, Simpkins J W. Transient cerebral ischemia induces aberrant neuronal cell cycle re-entry and Alzheimer's disease-like tauopathy in female rats. J Biol Chem 2004; 279: 22684–22692
   PubMed Web of Science ®Google Scholar
• Koistinaho M, Koistinaho J. Interactions between Alzheimer's disease and cerebral ischemia – focus on inflammation. Brain Res Brain Res Rev 2005; 48: 240–250
   PubMed Web of Science ®Google Scholar